ProShare Advisors LLC Has $2.25 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

ProShare Advisors LLC raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,114 shares of the biopharmaceutical company's stock after purchasing an additional 10,531 shares during the period. ProShare Advisors LLC's holdings in Halozyme Therapeutics were worth $2,253,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Halozyme Therapeutics by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock worth $634,999,000 after buying an additional 386,618 shares in the last quarter. Snyder Capital Management L P grew its position in Halozyme Therapeutics by 2.6% in the fourth quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock valued at $199,294,000 after acquiring an additional 105,086 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Halozyme Therapeutics by 2.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock worth $92,446,000 after acquiring an additional 47,795 shares in the last quarter. Northern Trust Corp raised its stake in Halozyme Therapeutics by 8.7% during the fourth quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock worth $87,386,000 after acquiring an additional 145,617 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock worth $85,254,000 after acquiring an additional 9,780 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the sale, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. This represents a 5.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 4,497 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the sale, the director now directly owns 28,611 shares of the company's stock, valued at $1,727,246.07. This represents a 13.58% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,697 shares of company stock worth $1,276,552. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Trading Up 1.5%

NASDAQ HALO traded up $0.79 on Monday, reaching $54.54. The company had a trading volume of 1,200,951 shares, compared to its average volume of 1,620,511. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of 15.90, a P/E/G ratio of 0.42 and a beta of 1.26. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.51. The business has a 50 day moving average of $59.88 and a two-hundred day moving average of $55.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business's quarterly revenue was up 35.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.79 earnings per share. Analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Upgrades and Downgrades

HALO has been the topic of several research reports. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price target for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Benchmark cut Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Leerink Partners downgraded Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a report on Tuesday, May 13th. Finally, JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of "Hold" and an average price target of $61.90.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.